secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGILENT TECHNOLOGIES, INC. (A)
CIK:        0001090872
Form:       8-K
Filed at:   2023-12-20T23:59:59+00:00
Accession:  0000950170-23-071756
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agilent moves Cell Analysis Division into Diagnostics and Genomics Group
------------------------------------------------------------------------

- Cell Analysis Division moved from LSAG to DGG; effective Q1 fiscal 2024.
- Reorganization aims to strengthen growth opportunities and align with customer workflows.
- Historical segment financials for three prior years will be recast and filed in January 2024.
- Cell Analysis built via acquisitions of BioTek, ACEA, and Seahorse; remains key growth driver.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1090872/000095017023071756/0000950170-23-071756-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1090872/000095017023071756/a-20231220.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-071756

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer